Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Target Price at $27.22

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have received a consensus recommendation of "Hold" from the nine ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $27.22.

A number of equities analysts recently weighed in on PCRX shares. Needham & Company LLC raised their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday, February 28th. Royal Bank of Canada reissued a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and upped their price objective for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright lifted their target price on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Finally, Barclays upped their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX traded up $0.65 during mid-day trading on Monday, reaching $22.69. 886,160 shares of the company were exchanged, compared to its average volume of 894,269. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $31.67. The company's 50 day moving average price is $23.78 and its 200 day moving average price is $19.16. The stock has a market capitalization of $1.05 billion, a PE ratio of -11.18 and a beta of 0.86. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Remove Ads

Institutional Trading of Pacira BioSciences

Several large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio raised its position in Pacira BioSciences by 21,458.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 91,192 shares of the company's stock valued at $1,718,000 after purchasing an additional 90,769 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Pacira BioSciences by 26.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,855 shares of the company's stock valued at $1,975,000 after acquiring an additional 21,781 shares in the last quarter. Voloridge Investment Management LLC raised its holdings in shares of Pacira BioSciences by 129.2% during the fourth quarter. Voloridge Investment Management LLC now owns 116,149 shares of the company's stock valued at $2,188,000 after acquiring an additional 65,467 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Pacira BioSciences by 72.2% in the fourth quarter. Squarepoint Ops LLC now owns 60,836 shares of the company's stock worth $1,146,000 after acquiring an additional 25,505 shares during the period. Finally, Two Sigma Advisers LP bought a new stake in Pacira BioSciences in the fourth quarter valued at $797,000. 99.73% of the stock is owned by institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.